List of Excipients in Branded Drug SPRIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	SPRIX	ketorolac tromethamine	54868-6284	EDETATE DISODIUM
Physicians Total Care Inc	SPRIX	ketorolac tromethamine	54868-6284	POTASSIUM PHOSPHATE, MONOBASIC
Physicians Total Care Inc	SPRIX	ketorolac tromethamine	54868-6284	SODIUM HYDROXIDE

SPRIX Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

SPRIX is ketorolac tromethamine nasal spray, an intranasal nonsteroidal anti-inflammatory drug approved for short-term management of moderately severe acute pain requiring opioid-level analgesia in adults. Its commercial value comes from rapid, nonoral delivery and use after surgery or when oral administration is impractical. The current excipient system is simple, but it creates opportunities for preservative-free packaging, improved nasal tolerability, device optimization, hospital distribution, and differentiated 505(b)(2) products.

The principal commercial constraint is duration. SPRIX is labeled for no more than five days because of ketorolac’s renal, gastrointestinal, bleeding, and cardiovascular risks. Excipient innovation therefore cannot rely on chronic-use positioning. It must improve onset, tolerability, handling, adherence, or institutional workflow.

What is SPRIX and how is it administered?

SPRIX contains ketorolac tromethamine at 15.75 mg per spray. The labeled dose is one spray in each nostril every six to eight hours, with a maximum of eight sprays in 24 hours. Patients younger than 65 years receive a maximum daily dose of 126 mg; older adults, renally impaired patients, and patients weighing less than 50 kg receive lower dosing under the prescribing information. Treatment is limited to five days [1].

Attribute	SPRIX
Active ingredient	Ketorolac tromethamine
Dosage form	Nasal spray
Strength	15.75 mg per spray
Route	Intranasal
FDA application	NDA 022382
Initial FDA approval	May 2010
Indication	Short-term management of moderately severe acute pain
Maximum treatment duration	Five days
Primary commercial advantage	Nonoral, rapid systemic NSAID delivery
Main safety limitations	Gastrointestinal bleeding, renal toxicity, bleeding risk, cardiovascular risk

SPRIX is not interchangeable with ophthalmic ketorolac, oral ketorolac, or injectable ketorolac. The product has its own nasal delivery system, dose limits, labeling, and administration instructions.

What excipients are used in SPRIX?

The marketed formulation uses a relatively short excipient list: sodium chloride, alcohol, disodium edetate, sodium hydroxide, and purified water [1].

Excipient	Likely formulation function
Sodium chloride	Tonicity adjustment
Alcohol	Solvent and potential antimicrobial-supporting agent
Disodium edetate	Chelating agent; may improve chemical stability
Sodium hydroxide	pH adjustment
Purified water	Vehicle

The label identifies the excipients but does not assign a separate commercial function to each component. The formulation is an aqueous nasal solution rather than a suspension, emulsion, liposomal system, or powder.

Why is the excipient system commercially relevant?

Intranasal products are sensitive to excipient selection because the formulation contacts nasal mucosa directly. Alcohol can contribute to local stinging or irritation. Sodium chloride affects osmolality and can influence comfort. Disodium edetate can alter preservative performance, metal-ion catalysis, and stability. Sodium hydroxide controls pH, which affects both ketorolac solubility and nasal tolerability.

For SPRIX, excipient strategy is therefore linked to four product attributes:

1. Nasal comfort during repeated dosing.
2. Chemical stability over the labeled shelf life.
3. Spray-pattern consistency.
4. Compatibility with the metered-dose device.

The short five-day treatment period reduces the need for a long-term mucosal-safety profile, but repeated dosing can still expose patients to up to 40 sprays per treatment course.

What formulation patents protect SPRIX?

SPRIX protection is likely to involve more than the ketorolac molecule itself. Ketorolac tromethamine is an established active ingredient, so commercial differentiation depends on formulation, nasal delivery, dosing, and manufacturing claims.

Potential claim categories include:

• Aqueous ketorolac tromethamine nasal solutions.
• Defined concentration and dose-volume ranges.
• pH and osmolality windows.
• Alcohol-containing or alcohol-reduced formulations.
• Chelator-containing formulations.
• Metered nasal spray devices.
• Spray plume, droplet-size, and dose-uniformity parameters.
• Methods of treating acute pain through intranasal ketorolac.
• Packaging systems that preserve stability and dose accuracy.

The relevant legal distinction is between patents listed for the NDA in the FDA Orange Book and broader patent families that may not be listed. Orange Book-listed patents can create ANDA Paragraph IV litigation risk. Unlisted formulation, device, process, or foreign patents can still affect freedom to operate, licensing value, and launch timing [2].

SPRIX received FDA approval in 2010. Any original regulatory exclusivity associated with the NDA would have expired years ago. Current market barriers therefore depend primarily on patent status, device rights, manufacturing capability, regulatory requirements, and commercial contracting rather than new-drug exclusivity.

When does SPRIX lose exclusivity?

SPRIX’s regulatory exclusivity period has expired. The key commercial questions are whether relevant patents remain enforceable, whether generic or 505(b)(2) applicants can establish pharmaceutical equivalence or rely on the reference product, and whether the nasal device creates a separate barrier.

Exclusivity category	SPRIX position
New chemical entity exclusivity	Not applicable to the 2010 approval
Three-year new clinical investigation exclusivity	Expired
Pediatric exclusivity	No current commercial significance identified from the original approval
Orphan exclusivity	Not applicable
Patent exclusivity	Must be assessed against current Orange Book and USPTO records
Device and formulation protection	Potentially relevant, especially for nasal-spray equivalence

A generic applicant may pursue an ANDA if it can meet FDA requirements for active ingredient, strength, dosage form, route, performance, labeling, and device-related characteristics. A product with meaningful formulation or device differences may instead require a 505(b)(2) application.

What excipient strategies could improve SPRIX?

Preservative-free unit-dose packaging

A preservative-free version is the clearest excipient and packaging opportunity. The present product uses alcohol and a multidose nasal-spray format. A preservative-free unit-dose or limited-dose device could reduce concerns about preservative exposure and microbial contamination.

The tradeoff is cost. Unit-dose packaging increases material use, filling complexity, shipping volume, and hospital waste. It may still be attractive for postoperative settings where dose control and infection-control procedures carry greater value than low packaging cost.

Reduced-alcohol formulation

A lower-alcohol or alcohol-free formulation could target nasal burning and improve repeat-dose acceptability. Such a change would require work on solubility, chemical stability, microbial control, spray performance, and container compatibility.

The main risk is that alcohol may contribute to the current product’s solubilization or stability profile. Removing it without replacing its function could produce precipitation, dose variability, or shorter shelf life.

Potential replacements include changes in pH, ionic strength, cosolvent selection, or drug concentration. Each replacement creates new safety and regulatory questions for intranasal use.

Mucoadhesive formulation

A mucoadhesive excipient could increase residence time and reduce post-administration runoff. Candidate classes include cellulose derivatives, polyvinyl polymers, and selected carbomers. The strategy is technically plausible but commercially difficult.

Excessive mucoadhesion can produce nasal obstruction, altered spray distribution, delayed absorption, or local irritation. A mucoadhesive system may also change the pharmacokinetic profile and could require a new clinical bridge rather than a simple pharmaceutical-equivalence package.

Improved isotonicity and pH control

A more tightly controlled pH and osmolality profile could improve comfort and reduce variability between patients. This is a lower-risk strategy than introducing a new polymer or lipid system, but the commercial differentiation may be modest.

The strongest opportunity would be a formulation that combines lower alcohol exposure with a validated nasal-comfort benefit while preserving the existing dose and device.

Barrier and stability packaging

Packaging can provide commercial value without changing the active formulation. Potential options include:

• Unit-dose ampoules.
• Low-extractables nasal containers.
• Improved moisture-barrier packaging.
• Dose counters.
• Tamper-evident components.
• Device systems with better priming and residual-volume control.

These changes may support a supplemental application, a 505(b)(2) product, or a device-led lifecycle strategy depending on the extent of the modification.

What regulatory pathway would apply to a new SPRIX formulation?

The pathway depends on whether the product is equivalent to the reference listed drug.

Product strategy	Likely pathway	Main regulatory burden
Same formulation and equivalent device	ANDA	Pharmaceutical equivalence, bioequivalence, device performance
Different excipients with same active and route	ANDA or 505(b)(2), depending on equivalence	Comparative pharmacokinetics, local tolerance, formulation justification
New absorption-enhancing or mucoadhesive system	505(b)(2)	Clinical bridging and safety characterization
New dose or dosing duration	505(b)(2) or full NDA	New efficacy and safety evidence
New combination product	505(b)(2) or NDA	Combination-product and clinical requirements
Preservative-free device variant	Potentially ANDA or 505(b)(2)	Microbial, stability, container-closure, and device data

FDA nasal-spray guidance emphasizes dose delivery, spray content uniformity, droplet-size distribution, plume geometry, device robustness, priming, repriming, and container-closure performance [3]. A formulation change cannot be evaluated independently from the actuator and container.

What generic-entry risks exist for SPRIX?

Generic-entry risk is moderate to high if the reference product’s formulation and device can be replicated without clinically meaningful differences. Ketorolac is an established active ingredient, and the labeled treatment duration limits the need for complex chronic-use studies.

The main barriers are:

• Demonstrating equivalent dose delivery.
• Matching spray performance.
• Establishing formulation stability.
• Addressing device supplier qualification.
• Resolving any Orange Book-listed patent challenges.
• Securing manufacturing capacity for a specialized nasal product.
• Convincing hospitals and prescribers to switch from the branded device.

A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman framework. Litigation risk would be highest where the NDA holder has listed formulation, device, or method-of-use patents with commercially relevant remaining terms [2,4].

A generic manufacturer may also launch at risk after patent certification, subject to litigation exposure. The commercial impact would likely be greatest in hospitals, ambulatory surgery centers, emergency departments, and specialty pain channels.

Which companies could compete with SPRIX?

Competition comes from both ketorolac products and alternative acute-pain therapies.

Competitive category	Examples	Commercial relevance
Injectable ketorolac	Generic ketorolac tromethamine injection	Strong hospital alternative; requires administration by healthcare personnel
Oral NSAIDs	Ibuprofen, naproxen, oral ketorolac	Low cost but unsuitable when oral administration is delayed or contraindicated
Opioids	Morphine, oxycodone, hydromorphone	Strong analgesia but involve respiratory, abuse, and dependence risks
Other nasal analgesics	Intranasal opioid or nonopioid products	Compete on onset, convenience, and nonoral delivery
Local anesthetic products	Intranasal or regional anesthetic systems	Relevant in selected procedural settings
Novel nonopioid analgesics	Emerging peripherally acting or centrally acting agents	Could reduce reliance on ketorolac or opioids

SPRIX’s strongest commercial position is as a nonopioid, nonoral rescue product. Its weakest position is in routine low-acuity pain, where oral NSAIDs are cheaper and easier to use.

What licensing and partnership opportunities exist?

The most credible licensing opportunities involve formulation and delivery technology rather than ketorolac itself.

Device licensing

A partner with a validated multidose or unit-dose nasal device could reduce development time and improve supply-chain reliability. Device licensing may also provide patent protection around dose delivery, spray geometry, or packaging.

Hospital-channel partnerships

A formulation designed for postoperative protocols could be bundled with enhanced-recovery pathways, ambulatory surgery kits, or hospital formulary programs. The value proposition is reduced reliance on injectable administration and lower opioid exposure.

Contract manufacturing

Nasal products require specialized filling, actuator assembly, priming studies, and stability programs. A contract development and manufacturing organization with nasal-device capabilities could become a strategic partner or acquisition target.

Regional commercialization

Rights could be divided by geography where regulatory status, hospital procurement, and ketorolac use patterns differ. The United States remains the most important reference market because of the FDA-approved product and Orange Book framework. Europe, Canada, and selected emerging markets require separate assessments of nasal ketorolac approval, device registration, and local patent rights.

How strong is the SPRIX patent estate?

The patent estate is strongest where it protects a complete product system rather than an isolated excipient. A claim directed only to a common excipient, such as sodium chloride or disodium edetate, would generally provide limited defensibility. Claims combining ketorolac concentration, pH, solvent system, nasal delivery parameters, and device characteristics are more commercially relevant.

Patent strength should be scored across five dimensions:

Factor	Strategic assessment
Active-ingredient exclusivity	Weak; ketorolac is established
Formulation claims	Potentially meaningful if narrow performance ranges are demonstrated
Device claims	Potentially strong if the device is difficult to replicate
Method-of-use claims	Narrow because treatment is limited to acute pain and five days
Manufacturing claims	Valuable if they solve stability, sterility, filling, or dose-uniformity problems

A new excipient formulation can create a fresh patent position only if it produces a defensible technical result, such as improved stability, reduced irritation, improved dose uniformity, or a clinically relevant pharmacokinetic advantage. Merely substituting one conventional excipient for another is unlikely to create durable exclusivity.

What is the revenue exposure and commercial upside?

SPRIX revenue is exposed to generic substitution, hospital formulary pressure, and the availability of inexpensive injectable and oral ketorolac. Product-specific revenue has not been consistently disclosed as a standalone public metric by the commercial rights holder, so valuation should use prescription volume, net price, payer mix, and institutional contracts rather than reported company-level revenue alone.

The most attractive commercial opportunities are:

1. A preservative-free product for hospital and ambulatory surgery use.
2. A lower-irritation formulation that maintains the current dose.
3. A better dose-counting or unit-dose device.
4. A generic or authorized-generic product with reliable supply.
5. A 505(b)(2) product targeting postoperative nonopioid protocols.
6. Regional licensing where branded nasal ketorolac has limited competition.

The least attractive strategy is a heavily reformulated product that adds excipients, changes absorption, and requires substantial clinical development without a clear improvement in patient outcomes.

Key Takeaways

• SPRIX contains ketorolac tromethamine in a simple aqueous nasal formulation with sodium chloride, alcohol, disodium edetate, sodium hydroxide, and purified water.
• The best excipient opportunity is a lower-irritation, preservative-free or reduced-alcohol formulation supported by a suitable device.
• Device performance is as important as excipient composition for regulatory approval and patent value.
• Original regulatory exclusivity has expired; current commercial protection depends on patents, device rights, manufacturing capability, and market access.
• Generic entry risk is significant because ketorolac is an established active ingredient and treatment is limited to five days.
• A 505(b)(2) strategy is more defensible for a materially improved formulation, device, or pharmacokinetic profile.
• Hospital, ambulatory surgery, and opioid-sparing protocols are the most relevant commercial channels.
• Strong patent protection requires a product-system claim combining formulation, delivery performance, and a demonstrated technical advantage.

FAQs

Can SPRIX be reformulated without changing the active ingredient?

Yes. A reformulation can retain ketorolac tromethamine while changing solvents, chelators, pH modifiers, tonicity agents, preservatives, or the delivery device. The regulatory pathway depends on whether the revised product remains equivalent to the reference listed drug.

Is alcohol in SPRIX necessary?

Alcohol is part of the labeled formulation, but the public label does not establish that it is indispensable. Removing or reducing it would require proof of acceptable solubility, stability, microbial control, nasal tolerability, and dose delivery.

Could a preservative-free SPRIX product obtain separate patent protection?

Yes, if the product includes a patentable combination of formulation, packaging, and performance characteristics. A preservative-free claim alone may be insufficient if it lacks unexpected technical or clinical advantages.

Would a ketorolac nasal powder be a generic SPRIX?

Not necessarily. A powder would differ in dosage form and device characteristics from the aqueous nasal spray. It would more likely require a 505(b)(2) or other regulatory pathway unless FDA determined that the product met applicable ANDA requirements.

What is the most valuable SPRIX lifecycle-management strategy?

A lower-irritation, preservative-free nasal spray with reliable dose counting and hospital-oriented packaging offers the clearest balance between technical feasibility, regulatory differentiation, and commercial value.

References

1. U.S. Food and Drug Administration. (2023). SPRIX (ketorolac tromethamine) nasal spray prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2002). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.